Tag #Drug Shortage

Showing 1 to 5 of 5 results

es.euronews.com

🌐 85% Global Worthiness

Sep 21, 13:19

EU Drug Shortages Reach Record Levels, Highlighting Systemic Issues

A European Court of Auditors report reveals record-high drug shortages in the EU in 2023 and 2024, caused by a lack of a common framework for managing shortages and fragmented data across member states, impacting patient care and highlighting the EU's strategic vulnerability in drug supply.

EU Drug Shortages Reach Record Levels, Highlighting Systemic Issues

A European Court of Auditors report reveals record-high drug shortages in the EU in 2023 and 2024, caused by a lack of a common framework for managing shortages and fragmented data across member states, impacting patient care and highlighting the EU's strategic vulnerability in drug supply.

Progress

16% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the key factors contributing to the severity of these shortages?

The main contributing factor is the absence of a common EU framework for managing shortages and the fragmentation of data across member states. Inconsistent reporting standards among EU countries, delayed or absent notifications to the EMA, and a lack of coercive mechanisms to ensure compliance from the pharmaceutical industry all exacerbate the problem.

us.cnn.com

🌐 85% Global Worthiness

Jul 16, 19:14

Bicillin L-A Shortage Threatens Progress Against Congenital Syphilis Crisis

Pfizer's announcement of a Bicillin L-A shortage, due to a recall of contaminated lots, threatens to worsen the US congenital syphilis crisis, reversing recent progress made through one-stop testing and treatment strategies, highlighting vulnerabilities in the drug supply chain and public health fun...

Bicillin L-A Shortage Threatens Progress Against Congenital Syphilis Crisis

Pfizer's announcement of a Bicillin L-A shortage, due to a recall of contaminated lots, threatens to worsen the US congenital syphilis crisis, reversing recent progress made through one-stop testing and treatment strategies, highlighting vulnerabilities in the drug supply chain and public health fun...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How will the shortage of Bicillin L-A impact efforts to control congenital syphilis rates in the US, given its crucial role in treating pregnant women with syphilis?

Pfizer, the sole US supplier of Bicillin L-A, a crucial antibiotic for treating syphilis in pregnant women, anticipates a shortage due to a July 10th recall of contaminated lots. This recall, stemming from faulty stoppers, follows a 2023 shortage and threatens efforts to combat rising congenital syphilis rates.

welt.de

🌐 75% Global Worthiness

Jan 14, 16:12

Dm to Sell Pharmacy-Only Medications Online Amidst German Pharmacy Decline

German drugstore chain dm will start selling non-prescription, pharmacy-only medications online due to a decreasing number of pharmacies in Germany (17,041 in 2023, lowest since 1978), rising healthcare costs, and anticipated regulatory changes. Dm aims to improve access to affordable healthcare pro...

Dm to Sell Pharmacy-Only Medications Online Amidst German Pharmacy Decline

German drugstore chain dm will start selling non-prescription, pharmacy-only medications online due to a decreasing number of pharmacies in Germany (17,041 in 2023, lowest since 1978), rising healthcare costs, and anticipated regulatory changes. Dm aims to improve access to affordable healthcare pro...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the long-term implications of dm's strategy for the structure and competition within Germany's pharmaceutical retail sector?

Dm's online expansion into pharmacy-only medications could reshape the German healthcare landscape. This could increase access to affordable medications in underserved areas and put pressure on traditional pharmacies to adapt. However, potential regulatory hurdles and resistance from established players could affect this plan's long-term success.

cnn.com

🌐 85% Global Worthiness

Jul 16, 16:16

Bicillin L-A Shortage Threatens Progress Against Congenital Syphilis

Pfizer warns of a Bicillin L-A shortage, impacting syphilis treatment during pregnancy, following a July recall of contaminated lots; the sole US supplier faces challenges in meeting demands, threatening recent progress against rising congenital syphilis rates.

Bicillin L-A Shortage Threatens Progress Against Congenital Syphilis

Pfizer warns of a Bicillin L-A shortage, impacting syphilis treatment during pregnancy, following a July recall of contaminated lots; the sole US supplier faces challenges in meeting demands, threatening recent progress against rising congenital syphilis rates.

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate consequences of the Bicillin L-A shortage for pregnant women with syphilis, given the drug's unique role and the absence of readily available alternatives?

Pfizer, the sole US supplier of Bicillin L-A, a crucial antibiotic for treating syphilis in pregnant women, anticipates a shortage. This follows a July recall due to contaminated lots, impacting efforts to combat rising congenital syphilis rates. The shortage could reverse recent progress in controlling the infection.

us.cnn.com

🌐 85% Global Worthiness

May 21, 16:12

FDA Ends Grace Period for Compounded GLP-1 Drugs, Raising Access Concerns

The FDA will end a grace period allowing the sale of compounded GLP-1 drugs for weight loss and diabetes, starting Thursday, impacting thousands of patients who rely on cheaper alternatives; brand-name drug shortages were declared over, leading to this decision.

FDA Ends Grace Period for Compounded GLP-1 Drugs, Raising Access Concerns

The FDA will end a grace period allowing the sale of compounded GLP-1 drugs for weight loss and diabetes, starting Thursday, impacting thousands of patients who rely on cheaper alternatives; brand-name drug shortages were declared over, leading to this decision.

Progress

56% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What factors contribute to the ongoing challenges in accessing GLP-1 medications, beyond the recent FDA decision?

The decision to halt compounded GLP-1 drug sales stems from the FDA's assertion that brand-name drug shortages have ended. However, concerns remain about the financial accessibility of brand-name alternatives, considering that many patients relied on compounded drugs due to lower cost. Insurance coverage complexities further complicate access, potentially jeopardizing ongoing treatment for many.

Showing 1 to 5 of 5 results